Varda raised a $250M Series D to scale pharmaceutical manufacturing in orbit. The company builds capsules for drug development and manufacturing in microgravity, with re-entry flights also used for hypersonic testing. Government customers account for roughly 70% of Varda’s payload customer base for 2027, with commercial pharmaceutical work making up the rest. The round was led by Lux Capital and Natural Capital.
- Company
- Varda varda.com
- Round
- Series D
- Amount
- $250M
- Source
- reuters.com
- In the newsletter
- No. 301, Toast for Factories